{"organizations": [], "uuid": "c5790911ef0f26ad9ea4eef2c3faa49ca65ae477", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/17/business-wire-bourne-partners-advises-accelovance-on-sale-to-linical.html", "country": "US", "domain_rank": 767, "title": "Bourne Partners Advises Accelovance on Sale to Linical", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-17T16:00:00.000+03:00", "replies_count": 0, "uuid": "c5790911ef0f26ad9ea4eef2c3faa49ca65ae477"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/17/business-wire-bourne-partners-advises-accelovance-on-sale-to-linical.html", "ord_in_thread": 0, "title": "Bourne Partners Advises Accelovance on Sale to Linical", "locations": [], "entities": {"persons": [{"name": "linical", "sentiment": "none"}, {"name": "bourne", "sentiment": "none"}, {"name": "stephen trevisan", "sentiment": "none"}], "locations": [{"name": "md.", "sentiment": "none"}, {"name": "linical rockville", "sentiment": "none"}, {"name": "accelovance", "sentiment": "none"}], "organizations": [{"name": "bourne partners", "sentiment": "negative"}, {"name": "accelovance, inc.", "sentiment": "neutral"}, {"name": "optimal research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ROCKVILLE, Md.--(BUSINESS WIRE)-- Accelovance, Inc. (“Accelovance”), a global contract research organization (CRO) focused on oncology, vaccines and general medicine, has been acquired by Linical, a leading, Asia-based CRO providing services in the areas of oncology and central nervous system to pharmaceutical companies worldwide.\nBourne Partners, a Charlotte-based financial advisory firm focused exclusively in healthcare and life sciences, served as the sole financial advisor to Accelovance throughout the transaction. Bourne Partners also facilitated the carve-out of Accelovance’s SMO business, Optimal Research, in the fourth quarter of 2017.\nStephen Trevisan, President and Chief Executive Officer of Accelovance, said, “Bourne Partners’ experienced execution team, deep domain knowledge and extensive strategic and PE relationships were critical in maximizing the value of the sale of Accelovance. I highly recommend them as a sell-side advisor in the Clinical CRO space.”\nBanks Bourne, Chief Executive Officer of Bourne Partners, said, “We are pleased to play a part in the trans-pacific connection of two leading CROs. This transaction, as well as the timely carve-out of Optimal Research, serves as a testament to the strong company Steve Trevisan and team have built over the past 13 years.”\nThe merger promotes a robust international presence, with the combined companies’ platform reaching through North America, Europe, and Asia Pacific.\nAbout Accelovance\nAccelovance is an award winning CRO focused on oncology, vaccine, dermatology, pain, nutrition and women’s health (Phase I-IV programs). Providing global full CRO services to pharmaceutical companies, biotechs, CROs, and academic institutions, Accelovance supports client needs by leveraging operational knowledge and patient recruitment strategies that result in successful clinical trials. Established in 2005 with a corporate mission to improve the quality and predictability in clinical research, Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise.\nFor more information, visit https://www.accelovance.com/ .\nAbout Bourne Partners\nBourne Partners is a financial services firm with over 15 years of specialized experience in the pharma, pharma services, OTC and consumer health sectors. Located in Charlotte, North Carolina, the company offers investment banking and advisory services, as well as direct investment opportunities.\nFor more information, visit http://bourne-partners.com/ .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180417005395/en/\nBourne Partners\nLindsey Stevens, 704-552-8407\nlstevens@bourne-partners.com\nSource: Bourne Partners", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbourne-partners.com%2F&esheet=51789836&newsitemid=20180417005395&lan=en-US&anchor=http%3A%2F%2Fbourne-partners.com%2F&index=2&md5=5231f8cc99beb450291ec2b0d0775f0e", "https://www.businesswire.com/news/home/20180417005395/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.accelovance.com%2F&esheet=51789836&newsitemid=20180417005395&lan=en-US&anchor=https%3A%2F%2Fwww.accelovance.com%2F&index=1&md5=121dc27e0781d55f7208a27ba05e0fef", "http://bourne-partners.com/", "https://www.accelovance.com/"], "published": "2018-04-17T16:00:00.000+03:00", "crawled": "2018-04-17T16:24:25.020+03:00", "highlightTitle": ""}